STOCK TITAN

[Form 4] Merck & Co., Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Mary Ellen Coe, identified as a director of Merck & Co. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 10 shares of Merck common stock and the acquisition of 357.4407 phantom stock units, each unit representing one share. The phantom units are tied to 357.4407 shares with a reference price of $83.93. The report lists total beneficial ownership following the transactions as 28,684.663 shares. The phantom units are to be settled 100% in cash upon the reporting person's termination of service under the plan's distribution schedule. The filing also notes holdings include shares from dividend reinvestment.

Mary Ellen Coe, identificata come direttrice di Merck & Co. (MRK), ha riferito operazioni datate 30/09/2025. La pratica mostra una cessione di 10 azioni ordinarie Merck e l'acquisizione di 357.4407 unità di azioni fantasma, ciascuna rappresentante una azione. Le unità fantasma sono legate a 357.4407 azioni con un prezzo di riferimento di 83,93 dollari. Il rapporto riporta una proprietà beneficiaria totale dopo le operazioni pari a 28.684,663 azioni. Le unità fantasma saranno liquidate interamente in contanti al termine del servizio del soggetto riportante secondo il piano di distribuzione. Il fascicolo segnala inoltre che le partecipazioni includono azioni provenienti da reinvestimento dei dividendi.
Mary Ellen Coe, identificada como directora de Merck & Co. (MRK), informó transacciones con fecha 30/09/2025. La presentación muestra una disposición de 10 acciones ordinarias Merck y la adquisición de 357.4407 unidades de acciones fantasma, cada una representando una acción. Las unidades fantasma están vinculadas a 357.4407 acciones con un precio de referencia de 83,93 dólares. El informe indica una titularidad beneficiosa total tras las operaciones de 28.684,663 acciones. Las unidades fantasma se liquidarán 100% en efectivo al finalizar el servicio del informante conforme al calendario de distribución del plan. El documento también señala que las participaciones incluyen acciones provenientes de reinversión de dividendos.
Mary Ellen Coe, Merck & Co.의 이사로 확인된 사람이 2025년 9월 30일자 거래를 보고했습니다. 서류에는 Merck 보통주 10주 처분과 357.4407주 가상의 주식 단위의 취득이 기재되어 있으며, 각 단위는 한 주를 나타냅니다. 가상 단위는 357.4407주와 연결되어 있으며 기준가격은 83.93달러입니다. 보고서는 거래 후 총 수익 귀속 주식 수를 28,684.663주로 나타냅니다. 가상 단위는 계획의 분배 일정에 따라 보고자 서비스 종료 시점에 현금으로 100% 정산됩니다. 또한 보유 주식에 배당 재투자에 의한 주식이 포함되어 있음을 명시하고 있습니다.
Mary Ellen Coe, identifiée comme administratrice de Merck & Co. (MRK), a déclaré des transactions datées du 30/09/2025. Le dépôt indique une cession de 10 actions ordinaires Merck et l'acquisition de 357.4407 unités d’actions fantômes, chaque unité représentant une action. Les unités fantômes sont liées à 357.4407 actions avec un prix de référence de 83,93 $. Le rapport indique une propriété bénéficiaire totale après les transactions de 28 684,663 actions. Les unités fantômes seront réglées intégralement en espèces lors de la fin de service de la personne déclarant, selon le calendrier de distribution du plan. Le dossier note également que les avoirs incluent des actions issues du réinvestissement des dividendes.
Mary Ellen Coe, als Direktorin von Merck & Co. (MRK) identifiziert, meldete Transaktionen mit Datum 30.09.2025. Die Einreichung zeigt eine Veräußerung von 10 Merck-Stammaktien und den Erwerb von 357,4407 Phantomaktieneinheiten, wobei jede Einheit eine Aktie darstellt. Die Phantomaktieneinheiten sind mit 357,4407 Aktien verbunden und haben einen Referenzpreis von 83,93 $. Der Bericht listet nach den Transaktionen das Gesamtmaß an beherrschendem Eigentum auf 28 684,663 Aktien. Die Phantomaktieneinheiten sollen beim Ausscheiden der meldenden Person vollständig in bar gemäß dem Verteilungsplan des Plans abgewickelt werden. Der Bericht stellt außerdem fest, dass die Bestände Dividenden-Reinvestitionen umfassen.
تم تحديد ماري إيلين كو كمديرة لشركة ميرك وشركاه (MRK) وقد أبلغت عن معاملات بتاريخ 30/09/2025. يظهر ملف الإيداع تصرفاً في 10 أسهم عادية من ميرك واستحواذ 357.4407 وحدة من الأسهم الشبحية، كل وحدة تمثل سهماً واحداً. ترتبط وحدات الشبح بـ 357.4407 أسهم مع سعر مرجعي قدره 83.93 دولاراً. يسجل التقرير ملكية مستفيدة إجمالية بعد المعاملات تبلغ 28,684.663 سهماً. ستُ تسوى وحدات الشبح البالغة 100% نقداً عند إنهاء خدمة الشخص المبلغ وفقاً لجدول توزيع الخطة. كما ي notes أن الحياint تتضمن أسهماً من إعادة استثمار الأرباح.
Mary Ellen Coe,被确认为 Merck & Co. (MRK) 的董事,报告了日期为 2025-09-30 的交易。备案显示处置 10 股 Merck 普通股,并取得 357.4407 股份的“幻影股票单位”,每单位代表一股。幻影单位与 357.4407 股相关,参考价为 83.93 美元。报告在交易后列出的实际受益所有权总量为 28,684.663 股。幻影单位将按计划分配表在报告人结束任职时100%以现金结算。备案还提到,持股包括来自再投资股息的股份。
Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small open-market disposition and grant of phantom units; reported beneficial ownership remains sizable but no material change to control.

The Form 4 records a minor disposal of 10 common shares alongside the grant/acquisition of 357.4407 phantom stock units that mirror 357.4407 common shares at a referenced price of $83.93. Phantom units are contractual and are to be paid in cash at termination, so they do not immediately change voting or dividend rights. The aggregate beneficial ownership reported after these items is 28,684.663 shares, which captures direct holdings plus reinvested dividends. From an investor-impacted metrics perspective, these entries are routine director compensation and small open-market activity rather than a material shift in ownership.

TL;DR: Disclosure aligns with standard director compensation practices; phantom units indicate deferred, cash-settled pay.

The filing documents director-level compensation in the form of phantom stock units with a 1-for-1 relationship to common shares and explicit cash settlement upon termination, consistent with deferred director pay plans. The disclosure clarifies the settlement mechanism and notes dividend reinvestment in existing holdings. There is no indication of changes to board composition or control, and the small sale quantity (10 shares) is immaterial to governance structure. Recordkeeping and disclosure appear complete for the reported items.

Mary Ellen Coe, identificata come direttrice di Merck & Co. (MRK), ha riferito operazioni datate 30/09/2025. La pratica mostra una cessione di 10 azioni ordinarie Merck e l'acquisizione di 357.4407 unità di azioni fantasma, ciascuna rappresentante una azione. Le unità fantasma sono legate a 357.4407 azioni con un prezzo di riferimento di 83,93 dollari. Il rapporto riporta una proprietà beneficiaria totale dopo le operazioni pari a 28.684,663 azioni. Le unità fantasma saranno liquidate interamente in contanti al termine del servizio del soggetto riportante secondo il piano di distribuzione. Il fascicolo segnala inoltre che le partecipazioni includono azioni provenienti da reinvestimento dei dividendi.
Mary Ellen Coe, identificada como directora de Merck & Co. (MRK), informó transacciones con fecha 30/09/2025. La presentación muestra una disposición de 10 acciones ordinarias Merck y la adquisición de 357.4407 unidades de acciones fantasma, cada una representando una acción. Las unidades fantasma están vinculadas a 357.4407 acciones con un precio de referencia de 83,93 dólares. El informe indica una titularidad beneficiosa total tras las operaciones de 28.684,663 acciones. Las unidades fantasma se liquidarán 100% en efectivo al finalizar el servicio del informante conforme al calendario de distribución del plan. El documento también señala que las participaciones incluyen acciones provenientes de reinversión de dividendos.
Mary Ellen Coe, Merck & Co.의 이사로 확인된 사람이 2025년 9월 30일자 거래를 보고했습니다. 서류에는 Merck 보통주 10주 처분과 357.4407주 가상의 주식 단위의 취득이 기재되어 있으며, 각 단위는 한 주를 나타냅니다. 가상 단위는 357.4407주와 연결되어 있으며 기준가격은 83.93달러입니다. 보고서는 거래 후 총 수익 귀속 주식 수를 28,684.663주로 나타냅니다. 가상 단위는 계획의 분배 일정에 따라 보고자 서비스 종료 시점에 현금으로 100% 정산됩니다. 또한 보유 주식에 배당 재투자에 의한 주식이 포함되어 있음을 명시하고 있습니다.
Mary Ellen Coe, identifiée comme administratrice de Merck & Co. (MRK), a déclaré des transactions datées du 30/09/2025. Le dépôt indique une cession de 10 actions ordinaires Merck et l'acquisition de 357.4407 unités d’actions fantômes, chaque unité représentant une action. Les unités fantômes sont liées à 357.4407 actions avec un prix de référence de 83,93 $. Le rapport indique une propriété bénéficiaire totale après les transactions de 28 684,663 actions. Les unités fantômes seront réglées intégralement en espèces lors de la fin de service de la personne déclarant, selon le calendrier de distribution du plan. Le dossier note également que les avoirs incluent des actions issues du réinvestissement des dividendes.
Mary Ellen Coe, als Direktorin von Merck & Co. (MRK) identifiziert, meldete Transaktionen mit Datum 30.09.2025. Die Einreichung zeigt eine Veräußerung von 10 Merck-Stammaktien und den Erwerb von 357,4407 Phantomaktieneinheiten, wobei jede Einheit eine Aktie darstellt. Die Phantomaktieneinheiten sind mit 357,4407 Aktien verbunden und haben einen Referenzpreis von 83,93 $. Der Bericht listet nach den Transaktionen das Gesamtmaß an beherrschendem Eigentum auf 28 684,663 Aktien. Die Phantomaktieneinheiten sollen beim Ausscheiden der meldenden Person vollständig in bar gemäß dem Verteilungsplan des Plans abgewickelt werden. Der Bericht stellt außerdem fest, dass die Bestände Dividenden-Reinvestitionen umfassen.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Coe Mary Ellen

(Last) (First) (Middle)
ALPHABET INC.
1600 AMPHITHEATRE PARKWAY

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock (1) 09/30/2025 A 357.4407 (2) (2) Common Stock 357.4407 $83.93 28,684.663(3) D
Explanation of Responses:
1. 1-for-1
2. Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
3. Holdings include shares acquired in dividend reinvestment transactions.
/s/ Kelly E. W. Grez as Attorney-in-Fact for Mary Ellen Coe 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Mary Ellen Coe report on the Form 4 for MRK?

The Form 4 shows a disposition of 10 shares of Merck common stock and the acquisition of 357.4407 phantom stock units on 09/30/2025.

How many shares does Mary Ellen Coe beneficially own after the reported transactions?

The filing reports total beneficial ownership of 28,684.663 shares following the reported transactions.

What is the settlement method for the phantom stock units reported?

The phantom stock units are to be settled 100% in cash upon the reporting person's termination of service, per the plan's distribution schedule.

What price is referenced for the phantom stock units?

The filing references a price of $83.93 for the underlying common stock amount associated with the phantom units.

Do the phantom stock units convert to voting shares immediately?

No. The phantom units are cash-settled upon termination and do not indicate immediate conversion to voting common shares.
Merck & Co

NYSE:MRK

MRK Rankings

MRK Latest News

MRK Latest SEC Filings

MRK Stock Data

225.13B
2.50B
0.07%
80.59%
0.95%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
RAHWAY